Testing for HER2 positivity in patients diagnosed with breast cancer to determine eligibility for treatment with trastuzumab

Medical Services Advisory Committee
Record ID 32015000410
Authors' recommendations: After considering the strength of the available evidence in relation to the safety, effectiveness and cost effectiveness, MSAC advised the Minister that it supported the extension of the MBS listing of in situ hybridisation (ISH) testing of tumour tissue from a patient with breast cancer to include its use to support the PBAC-recommended extension of the PBS listing of trastuzumab to include trastuzumab use in the neoadjuvant setting.
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Australia
MeSH Terms
  • Breast Neoplasms
  • Antibodies, Monoclonal, Humanized
  • Receptor, ErbB-2
Organisation Name: Medical Services Advisory Committee
Contact Address: MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name: msac.secretariat@health.gov.au
Contact Email: msac.secretariat@health.gov.au
Copyright: Medical Services Advisory Committee (MSAC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.